BioGeneration Ventures

Avidicure is a cancer care company focused on enhancing immune system function through innovative therapies. It is developing a novel antibody modality known as "AVC-Boosters," which are dual agonistic and multifunctional, engineered to deliver targeted and effective monotherapy. This approach aims to provide broad applicability in oncology, addressing various cancer types while prioritizing safety and efficacy. Currently, Avidicure is operating in stealth mode, indicating a focus on research and development before public engagement.

Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.

Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.

Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Artica Therapeutics focuses on biotechnological research and development aimed at creating innovative therapies for severe autoimmune and inflammatory disorders. The company employs label-free cellular-based screening methods to facilitate the rapid advancement of drug candidates. This approach enhances the efficiency of the drug discovery process, ultimately enabling healthcare professionals to provide effective treatments for patients suffering from these challenging conditions. Additionally, Artica Therapeutics is involved in the development of medical devices and pharmaceutical processes, expanding its impact within the healthcare sector.

Tessellate BIO is a preclinical biotechnology company that specializes in advanced Synthetic Lethality techniques aimed at addressing cancers with significant unmet medical needs. The company develops precision oncology methods designed to target tumors that rely on synthetic lethality mechanisms. By focusing on innovative biotechnological research and development, Tessellate BIO seeks to revolutionize cancer treatments and improve outcomes for patients facing challenging cancers.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

Panome Bio is a biomarker discovery platform based in Saint Louis, Missouri, established in 2022. The company focuses on metabolomics technologies that facilitate biomarker discovery and metabolite profiling. Its services include metabolomics, lipidomics, and proteomics screening through untargeted analysis and proprietary computational methods. Panome Bio offers comprehensive workflows and personalized data analysis reports, enabling clients to gain a global and unbiased view of the metabolome, which encompasses a wide range of diverse metabolites in biological systems.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

FundaMental Pharma is a neuroscience company focused on developing innovative treatments for neurological diseases at the preclinical stage. The company creates neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. Utilizing peptides and gene therapy, FundaMental Pharma specializes in diagnosing polymorphisms and is dedicated to developing a novel class of drugs that target untreatable neurological conditions. Through its research, the company seeks to provide pharmacological solutions for patients suffering from various challenging neurological disorders.

Phosphoenix is a neurotechnology company that originated from the NESTOR program, which was supported by the Netherlands Organisation for Scientific Research. The company focuses on developing a chronically implanted wireless device designed to restore functional vision for individuals who have lost their sight. This innovative device bypasses the eyes and creates a direct interface with the brain, utilizing fundamental neuroscience principles to offer practical clinical applications. By enabling users to recognize objects and navigate more independently, Phosphoenix aims to enhance the quality of life for those with vision impairments, providing them with a means to regain rudimentary vision and improve their overall independence. The founding team consists of leading neuroscientists, electronic engineers, and entrepreneurs, emphasizing a strong multidisciplinary approach to addressing vision loss.

Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

River BioMedics is a biotechnology company focused on developing 3D human heart tissue models for pre-clinical drug testing. Recognizing that pharmaceutical companies face significant costs and high failure rates in drug development, particularly due to drug-induced cardiac toxicity, the company aims to enhance drug discovery processes. By creating realistic 3D cardiac tissues that mimic the functioning human heart, River BioMedics provides advanced tools for toxicity screening and target validation. These innovative models offer healthcare professionals valuable insights into the effects of various compounds on cardiac function, thereby facilitating the development of novel cardiac drugs and improving the overall efficiency of drug discovery.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Dunad Therapeutics is a biopharmaceutical company dedicated to developing innovative targeted protein degradation therapies. The company utilizes a small molecule platform that induces the selective degradation of disease-causing and often difficult-to-target proteins by directly modulating their stability and conformation. This approach offers a novel molecular strategy that is adaptable and operates through a mechanism of action that is not limited to specific target classes, distinguishing it from existing targeted protein degradation technologies. By focusing on oral therapies, Dunad Therapeutics aims to provide effective treatment options for challenging diseases.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Azafaros B.V., based in Leiden, the Netherlands, is focused on developing therapeutic agents for rare metabolic disorders, particularly lysosomal storage disorders (LSDs). The company specializes in oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the central nervous system and interfering with the metabolism of glycosphingolipids. Through a unique dual mode of action, Azafaros seeks to improve the lives of patients suffering from these severe and often life-threatening inherited diseases.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Tiga TX develops an IgA therapeutic monoclonal antibody platform to activate neutrophils for the treatment of solid tumors.

Fibrocor Therapeutics L.P. is a biotechnology company based in Toronto, Canada, established in 2017. The company specializes in the development of tissue-specific therapeutics aimed at addressing the underlying causes of fibrotic diseases affecting the kidneys and other organs. Fibrocor focuses on identifying and targeting critical pathways involved in the fibrogenic process, utilizing patient-derived tissue samples to uncover novel disease targets. The company has advanced a lead program and has partnered with Evotec to facilitate the development of innovative therapeutic molecules.

Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for those suffering from metabolic conditions where existing treatments are insufficient or poorly tolerated. Its lead product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to address the shortcomings of current LDL-C lowering therapies. Through its focus on transformative solutions, NewAmsterdam Pharma seeks to make a significant impact in the management of cardio-metabolic diseases.

Genase Therapeutics is the developer of therapeutic products intended to treat solid tumors. The company develops small molecule inhibitors against a metabolic target with therapeutic potential in hematologic malignancies as well as conducting research in the field of oncology, providing pharmaceuticals and healthcare professionals with biotechnological research and development work in the field of oncology.

Azafaros B.V., based in Leiden, the Netherlands, is focused on developing therapeutic agents for rare metabolic disorders, particularly lysosomal storage disorders (LSDs). The company specializes in oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the central nervous system and interfering with the metabolism of glycosphingolipids. Through a unique dual mode of action, Azafaros seeks to improve the lives of patients suffering from these severe and often life-threatening inherited diseases.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Escalier Biosciences B.V., established in 2016 and headquartered in Nijmegen, Netherlands, is a biopharmaceutical company focused on developing novel small molecule therapeutics for autoimmune disorders, particularly psoriasis. The company is advancing its lead drug candidates, which are designed to target ROR?t, through late-stage preclinical studies. Escalier's therapeutics enhance penetration in dermal tissues, optimizing target engagement at sites of inflammation while reducing the potential for systemic side effects and immune suppression. In addition to its operations in the Netherlands, Escalier also maintains an office in Encinitas, California.

Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Mellon Medical B.V., established in 2013 and headquartered in Nijmegen, the Netherlands, specializes in the development and marketing of innovative suturing tools designed for surgical applications. The company focuses on creating instruments that enable surgeons to perform single-handed stitching, thereby enhancing the efficiency and effectiveness of suturing tubular and layered structures during medical procedures. By providing advanced suturing solutions, Mellon Medical aims to improve patient outcomes and support medical specialists in delivering high-quality healthcare.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.

Cristal Therapeutics BV is a clinical-stage pharmaceutical company based in Maastricht, the Netherlands, founded in 2011. The company specializes in developing nanomedicines using its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted therapy. This advanced technology aims to enhance the efficacy of both new and existing drugs by improving their delivery to specific tissues and cells, thereby addressing significant medical needs, particularly in cancer treatment. Cristal Therapeutics focuses on creating versatile nanomedicine solutions that can facilitate better outcomes in various therapeutic areas through innovative polymeric constructs.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.

Cristal Therapeutics BV is a clinical-stage pharmaceutical company based in Maastricht, the Netherlands, founded in 2011. The company specializes in developing nanomedicines using its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted therapy. This advanced technology aims to enhance the efficacy of both new and existing drugs by improving their delivery to specific tissues and cells, thereby addressing significant medical needs, particularly in cancer treatment. Cristal Therapeutics focuses on creating versatile nanomedicine solutions that can facilitate better outcomes in various therapeutic areas through innovative polymeric constructs.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.

Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, specializing in the development of antibody-drug conjugate (ADC) technology for oncology applications. Founded in 2010, the company has created proprietary platforms, including GlycoConnect and HydraSpace, which enhance the efficacy and tolerability of ADCs. GlycoConnect facilitates site-specific and stable conjugation of anti-cancer molecules by modifying naturally-occurring glycan anchor points on antibodies, while HydraSpace improves payload solubility and reduces aggregation potential. Additionally, Synaffix offers a metal-free click chemistry, applicable across the pharmaceutical, biotech, and academic sectors, which allows for the efficient development of ADCs without prior genetic modifications. The company's patent portfolio ensures protection of its innovations and resulting products through at least 2035.

Staten Biotechnology B.V., founded in 2014 and headquartered in Nijmegen, the Netherlands, focuses on researching, developing, and producing therapeutics aimed at treating dyslipidemia and reducing cardiovascular mortality. The company specializes in a human monoclonal antibody that targets apoC3, a protein implicated in triglyceride metabolism. By neutralizing apoC3, Staten's antibody helps decrease the accumulation of lipids and triglycerides in the blood, thereby potentially lowering the risk of vascular and heart diseases.

Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. Acerta Pharma was acquired by AstraZeneca in February 2016. Acerta Pharma was founded in 2013 and is based in San Carlos, California.

Dezima Pharma B.V., founded in 2012 and based in Naarden, the Netherlands, focuses on developing protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company is known for its innovative approach in creating a cholesteryl ester transfer protein inhibitor, which serves as a pharmacological therapy to reduce low-density lipoprotein cholesterol levels. By lowering these cholesterol levels, Dezima Pharma aims to provide clinicians with effective treatment options for patients suffering from dyslipidemia and related cardiovascular conditions.

SurgVision BV is a Netherlands-based company that specializes in developing near-infrared fluorescence molecular imaging technology for clinical applications. Founded in 2011, SurgVision focuses on creating innovative solutions for fluorescence image-guided surgery, utilizing high-definition cameras and molecular probes. The company's Multi-Spectral Normalized Imaging platform enables precise visualization of healthy and cancerous tissues, particularly in breast cancer surgeries, allowing surgeons to effectively distinguish between various tissue types. As of October 2017, SurgVision operates as a subsidiary of Bracco Imaging S.p.A.

Lanthio Pharma B.V. is a biopharmaceutical company based in Groningen, the Netherlands, specializing in the discovery and development of lantipeptide drugs aimed at treating conditions such as fibrosis, stroke, heart failure, and multiple sclerosis. The company employs its proprietary lanthionine-peptide drug discovery technology, LanthioPep™, to create novel peptide therapeutics that exhibit enhanced resistance to peptidase degradation and high receptor specificity. Among its product pipeline are LP2, designed to target fibrosis; PanCyte, intended for ischemic stroke recovery and related conditions; a Lanthi-apelin agonist for various organ systems; and Lanthi-galanin for multiple sclerosis. Founded in 2010, Lanthio Pharma operates as a subsidiary of Morphosys AG, focusing on generating stable, peptidase-resistant peptides that possess high intrinsic activity for several G-protein-coupled receptor targets.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

Medisse is a Dutch company, founded in 2006, that develops, produces and markets resorbable soft tissue implants, based on bio-resorbable PTMC polymers. Medisse does yet not have commercial products but is working on the testing of its first product before market introduction. Medisse's first product will be an anti-adhesion barrier.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

FlexGen is an innovative biotech company based in Leiden, the Netherlands. FlexGen is a spin-off from Leiden University Medical Centre (LUMC) and Dutch Space (part of EADS) and has proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. FlexGen commercializes the FlexArrayer, a bench-top instrument for custom microarray and oligopool synthesis. FlexGen works at the forefront of innovative microarray and oligopool applications.

Progentix Orthobiology is a Netherlands-based manufacturer specializing in orthopedic bone graft materials. Located in Bilthoven, the company focuses on developing a range of osteoinductive products designed for clinical application in bone regenerative surgery. Progentix Orthobiology's offerings also extend to spinal medical devices and minimally invasive surgical solutions, catering to the needs of healthcare professionals in the field of orthobiology.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.

NovioGendix is a privately-held molecular diagnostics company based in Nijmegen, The Netherlands, specializing in the development of non-invasive liquid biopsy tests for prostate cancer. Established in 2008 as a spin-off from Radboud University Medical Center, NovioGendix collaborates closely with various departments of the institution. The company is focused on creating advanced and clinically relevant molecular diagnostic assays for uro-oncological practices, and it has a portfolio of diagnostic tests for prostate, bladder, kidney, and other urologic cancers at different stages of development. NovioGendix provides its services to physicians, clinics, and hospitals, aiming to enhance cancer treatment through innovative diagnostic solutions. Major shareholders include BioGeneration Ventures and Participatiemaatschappij Oost Nederland.

Azafaros B.V., based in Leiden, the Netherlands, is focused on developing therapeutic agents for rare metabolic disorders, particularly lysosomal storage disorders (LSDs). The company specializes in oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the central nervous system and interfering with the metabolism of glycosphingolipids. Through a unique dual mode of action, Azafaros seeks to improve the lives of patients suffering from these severe and often life-threatening inherited diseases.